For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Exact Sciences Corp. (NASDAQ: EXAS) closed the day trading at $60.96 down -3.97% from the previous closing price of $63.48. In other words, the price has decreased by -$3.97 from its previous closing price. On the day, 2.17 million shares were traded. EXAS stock price reached its highest trading level at $63.48 during the session, while it also had its lowest trading level at $60.37.
Ratios:
For a better understanding of EXAS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 346.57. For the most recent quarter (mrq), Quick Ratio is recorded 2.07 and its Current Ratio is at 2.32. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.79.
On December 14, 2023, Guggenheim started tracking the stock assigning a Buy rating and target price of $90.
On December 13, 2023, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $95.Wolfe Research initiated its Outperform rating on December 13, 2023, with a $95 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 02 ’24 when Baranick Brian sold 924 shares for $79.43 per share. The transaction valued at 73,393 led to the insider holds 13,171 shares of the business.
Condella Sarah sold 2,000 shares of EXAS for $140,000 on Apr 01 ’24. The EVP, Human Resources now owns 71,787 shares after completing the transaction at $70.00 per share. On Mar 28 ’24, another insider, Condella Sarah, who serves as the EVP, Human Resources of the company, sold 2,000 shares for $70.00 each. As a result, the insider received 140,000 and left with 73,787 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 11066130432 and an Enterprise Value of 12855108608. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.43 while its Price-to-Book (P/B) ratio in mrq is 3.52. Its current Enterprise Value per Revenue stands at 5.143 whereas that against EBITDA is -125.751.
Stock Price History:
The Beta on a monthly basis for EXAS is 1.25, which has changed by -0.07929313 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, EXAS has reached a high of $100.77, while it has fallen to a 52-week low of $56.05. The 50-Day Moving Average of the stock is -3.62%, while the 200-Day Moving Average is calculated to be -14.24%.
Shares Statistics:
Over the past 3-months, EXAS traded about 2.42M shares per day on average, while over the past 10 days, EXAS traded about 2710340 shares per day. A total of 181.36M shares are outstanding, with a floating share count of 179.65M. Insiders hold about 1.04% of the company’s shares, while institutions hold 87.65% stake in the company. Shares short for EXAS as of 1711584000 were 6339844 with a Short Ratio of 2.62, compared to 1709164800 on 7038595. Therefore, it implies a Short% of Shares Outstanding of 6339844 and a Short% of Float of 3.52.
Earnings Estimates
The market rating for Exact Sciences Corp. (EXAS) is a result of the insights provided by 16 analysts actively involved in the assessment.On average, analysts expect EPS of -$0.47 for the current quarter, with a high estimate of -$0.17 and a low estimate of -$0.63, while EPS last year was -$0.42. The consensus estimate for the next quarter is -$0.23, with high estimates of -$0.09 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.31 and -$1.29 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is $0.06, with 17 analysts recommending between $0.81 and -$0.64.
Revenue Estimates
20 analysts predict $627.36M in revenue for the current quarter. It ranges from a high estimate of $647M to a low estimate of $619.99M. As of the current estimate, Exact Sciences Corp.’s year-ago sales were $602.45M, an estimated increase of 4.10% from the year-ago figure. For the next quarter, 20 analysts are estimating revenue of $700.15M, an increase of 12.50% over than the figure of $4.10% in the same quarter last year. There is a high estimate of $721.08M for the next quarter, whereas the lowest estimate is $682M.
A total of 22 analysts have provided revenue estimates for EXAS’s current fiscal year. The highest revenue estimate was $2.87B, while the lowest revenue estimate was $2.82B, resulting in an average revenue estimate of $2.83B. In the same quarter a year ago, actual revenue was $2.5B, up 13.30% from the average estimate. Based on 21 analysts’ estimates, the company’s revenue will be $3.23B in the next fiscal year. The high estimate is $3.36B and the low estimate is $3.17B. The average revenue growth estimate for next year is up 13.90% from the average revenue estimate for this year.
